Apixaban is also used to treat DVT or pulmonary embolism (PE), and to lower your risk of having a repeat DVT or PE.Apixaban may also be used for purposes not listed in this medication guide.Apixaban side effectsGet emergency medical help if you have signs of an allergic reaction: hives;...
Currently, apixaban is US FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery, for the treatment of DVT and PE, and...
The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE [seeClinical Studies]. Missed Dose If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-d...
The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE [seeClinical Studies]. Missed Dose If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-d...
Apixaban has been investigated in the context of COVID-19. Based on a thorough literature review, the current guidelines from the National Institutes of Health (NIH) state that there is insufficient evidence to recommend the use of a therapeutic dose of apixaban for prophylaxis against venous thro...
ESRD maintained on hemodialysis: 5 mg BID; decrease dose to 2.5 mg BID if 1 additional characteristic of age ≥80 years or weight ≤60 kg is present Postoperative Prophylaxis of DVT/PE Indicated following hip or knee replacement surgery Initial: Give 2.5 mg PO 12-24 hr after surgery Duration...
It is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. It is also indicated for the treatment of PE and for the treatment of DVT. Finally, apixaban; is indicated it...
In the acute phase of thrombosis (median time of 4 months), we used therapeutic dose of DOACs; the 32 patients with permanent thrombotic risk factors or without recanalization of the UEDVT were shifted to low-dose DOACs (apixaban 2.5mg twice daily or rivaroxaban 10mg daily). During therapy ...
Apixaban has been studied for use in VTE prophylaxis, treatment of acute thromboembolism, and stroke prevention in AF. Compared with prophylactic enoxaparin, apixaban was shown to be as effective at preventing DVT and PE in patients undergoing knee replacement but was associated with fewer or a sim...
Venous ThromboembolismProphylaxis after Surgery Hip Replacement: 2.5 mg orally twice daily for 35 days KneeReplacement: 2.5 mg orally twice daily for 12 days AcuteHeparin Induced Thrombocytopenia(not FDA approved) Take 5 mg orally twice daily (untilPlatelet Counts return to normal) ...